Sensei keeps its eye on VISTA
The micro cap promises data this year, but its peer Kineta winds down a VISTA trial.
Astra takes Steap2 into human trials
First-in-human clinical trial listings include AZD0754, Astra’s internally developed Car-T therapy.
Warning signs for Xencor
Data on the group’s lead project, the PD-1 x CTLA-4 bispecific vudalimab, are far from emphatic.
Janux gives conditionally acting therapeutics hope
Early activity of JANX007 in prostate cancer sees Janux stock gain 190%.
Revolution pushes home its pan-KRAS advantage
Not long after starting phase 1, RMC-6236 could be in pivotal trials this year.
Arcus makes its HIF2α pitch
After living in the shadow of Arcus’s TIGIT project, casdatifan might soon come into its own.
Safety remains in focus for Cogent’s bezuclastinib
An “optimised formulation” of bezuclastinib looks promising, but the safety question remains open.
Mesothelin lives on
Work targeting mesothelin, and some other antigens that have hitherto disappointed, continues.
